University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Boris C. Bastian, MD, PhD

Boris C. Bastian, MD, PhD

Professor of Dermatology and Pathology, University of California, San Francisco
Gerson and Barbara Bass Bakar Distinguished Professor in Cancer Research, UCSF

Cancer Center Program Memberships

Cancer Genetics

Research Summary

I am a dermatologist and dermatopathologistwith expertise in diagnosing and treating patients with cutaneous neoplasms. I have expertise in molecular cancer genetics and molecular pathology and lead a research laboratory at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF). Since 1997 my research has focused on the molecular pathogenesis of melanoma and revealed the existence of distinct disease subtypes that differ in their underlying genetic alterations, epidemiology, anatomic distribution, clinical and microscopic appearance, evolution from precursor lesions, role of UV radiation, and cell of origin. The Bastian Lab also has contributed to the discovery of oncogenic alterations such as mutations in KIT, GNAQ, GNA11, HRAS, and a whole panel of oncogenic fusion genes of various receptor tyrosine and threonine kinases in various melanocytic neoplasms. I have developed clinical tests to assist pathologists with the diagnosis of histologically ambiguous lesions, which have been adopted word-wide. I have proposed a two-dimensional taxonomy of melanocytic neoplasia that has been adopted as the framework for the revised WHO Classification of Skin Tumors. I founded and direct the Clinical Cancer Genomics Laboratory at UCSF, which performs genomic analyses of tumor samples of patients seen at the UCSF Helen Diller Family Comprehensive Cancer Center and have additional clinical responsibilities in the in the Dermatopathology Section of the Departments of Dermatology and Pathology.

Education

Humboldt-Gymnasium, Solingen, Germany, Baccalaureate, 1980
University of Munich, Germany, M.D., 1988, Medicine
University of Munich, Germany, Dr. med., 1989, Laboratory Medicine
University of Wurzburg, Germany, Residency, 1994, Dermatology
University of California, San Francisco, Postdoctoral, 1999, Cancer Genetics


Professional Experience

  • 1986-1989
    Dissertation 'Development and Characterization of an enzymatic assay for human pancreatic phospholipase A2'
  • 1988-89
    Fellowship, Dept. of Hematology, Ludwig-Maximilian-University, Munich, Germany
  • 1989-1994
    Residency, Dermatology, Dept. of Dermatology, University of Würzburg, Germany
  • 1993
    German board certification for Dermatology
  • 1995
    German board certification Allergy and Immunology
  • 1994-1997
    Attending Physician, Dept. of Dermatology, University of Würzburg, Germany
  • 1995-1997
    Director of the Dermatopathology Section, Dept. of Dermatology, University of Würzburg, Germany
  • 1997-1999
    Postdoctoral Fellowship, Cancer Genetics Group, Cancer Center at UCSF
  • 1999-2002
    Assistant Clinical Professor, Dept. of Dermatology and Pathology, UCSF
  • 2002-2004
    Assistant Professor in Residence, Department of Dermatology and Assistant Clinical Professor, Department of Pathology, UCSF
  • 7/2004-2008
    Associate Professor in Residence, Department of Dermatology and Associate Clinical Professor, Department of Pathology, UCSF
  • 7/2008
    Professor in Residence, Department of Dermatology and Clinical Professor, Department of Pathology, UCSF
  • 9/2008
    Leader, Cutaneous Oncology Program, UCSF
  • 4/2010-8/11
    Chairman, Department of Pathology, and Member, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
  • 9/2011-present
    Professor of Dermatology and Pathology, University of California, San Francisco

Honors & Awards

  • 1995
    Graduate Stipend of the Novartis Foundation for Therapeutic Research
  • 1997
    Habilitandenstipendium of the German Research Society (Deutsche Forschungsgemeinschaft)
  • 2000
    American Melanoma Foundation Research Award
  • 2001
    American Skin Association Research Scientist Development Award
  • 2005
    Hermann Pinkus Lectureship and Award, American Society of Dermatopathology
  • 2006
    Stewart Trust Award
  • 2007
    Melanoma Research Foundation Individual Investigator Award
  • 2008
    Abby S. and Howard P. Milstein Innovation Award for Skin Cancer Research, American Skin Association
  • 2011-2013
    President, Society of Melanoma Research
  • 2011
    German National Academy of Science (Leopoldina)
  • 2012
    Helwig Award, American Society of Dermatopathology
  • 2012
    Scientific Leadership Award, Melanoma Research Foundation
  • 2014
    Lifetime Achievement Award, Society of Melanoma Research
  • 2015
    Stein Innovation Award, Research to Prevent Blindness
  • 2016
    Research Achievement Award in Melanoma and Skin Cancer Research, American Skin Association
  • 2017
    Lila and Murray Gruber Memorial Cancer Research Award, American Academy of Dermatology
  • 2017
    NCI Outstanding Investigator Award

Selected Publications

  1. Stevers M, Rabban JT, Garg K, Van Ziffle J, Onodera C, Grenert JP, Yeh I, Bastian BC, Zaloudek C, Solomon DA. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Mod Pathol. 2018 Aug 31.
    View on PubMed
  2. Webster JD, Pham TH, Wu X, Hughes NW, Li Z, Totpal K, Lee HJ, Calses PC, Chaurushiya MS, Stawiski EW, Modrusan Z, Chang MT, Tran C, Lee WP, Chalasani S, Hung J, Sharma N, Chan S, Hotzel K, Talevich E, Shain A, Xu M, Lill J, Dixit VM, Bastian BC, Dey A. The tumor suppressor BAP1 cooperates with BRAFV600E to promote tumor formation in cutaneous melanoma. Pigment Cell Melanoma Res. 2018 Aug 29.
    View on PubMed
  3. Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Bastian BC, Grenert JP, Kline CN, Mueller S, Banerjee A, Nicolaides T, Gupta N, Berger MS, Lee HS, Pekmezci M, Tihan T, Bollen AW, Perry A, Shieh JTC, Solomon DA. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathol. 2018 Jul 27.
    View on PubMed
  4. Solomon DA, Korshunov A, Sill M, Jones DTW, Kool M, Pfister SM, Fan X, Bannykh S, Hu J, Danielpour M, Li R, Johnston J, Cham E, Cooney T, Sun PP, Oberheim Bush NA, McDermott M, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Villanueva-Meyer JE, Pekmezci M, Bollen AW, Perry A. Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. Acta Neuropathol. 2018 Jul 13.
    View on PubMed
  5. Zeng H, Jorapur A, Shain AH, Lang UE, Torres R, Zhang Y, McNeal AS, Botton T, Lin J, Donne M, Bastian IN, Yu R, North JP, Pincus L, Ruben BS, Joseph NM, Yeh I, Bastian BC, Judson RL. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. Cancer Cell. 2018 Jul 09; 34(1):56-68.e9.
    View on PubMed
  6. Shain AH, Joseph NM, Yu R, Benhamida J, Liu S, Prow T, Ruben B, North J, Pincus L, Yeh I, Judson R, Bastian BC. Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution. Cancer Cell. 2018 Jul 09; 34(1):45-55.e4.
    View on PubMed
  7. Pekmezci M, Villanueva-Meyer JE, Goode B, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Chamyan G, Maher OM, Khatib Z, Kleinschmidt-DeMasters BK, Samuel D, Mueller S, Banerjee A, Clarke JL, Cooney T, Torkildson J, Gupta N, Theodosopoulos P, Chang EF, Berger M, Bollen AW, Perry A, Tihan T, Solomon DA. The genetic landscape of ganglioglioma. Acta Neuropathol Commun. 2018 Jun 07; 6(1):47.
    View on PubMed
  8. Goode B, Mondal G, Hyun M, Ruiz DG, Lin YH, Van Ziffle J, Joseph NM, Onodera C, Talevich E, Grenert JP, Hewedi IH, Snuderl M, Brat DJ, Kleinschmidt-DeMasters BK, Rodriguez FJ, Louis DN, Yong WH, Lopes MB, Rosenblum MK, Butowski N, Tihan T, Bollen AW, Phillips JJ, Wiita AP, Yeh I, Jacobson MP, Bastian BC, Perry A, Solomon DA. A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nat Commun. 2018 02 23; 9(1):810.
    View on PubMed
  9. Iorgulescu JB, Van Ziffle J, Stevers M, Grenert JP, Bastian BC, Chavez L, Stichel D, Buchhalter I, Samuel D, Nicolaides T, Banerjee A, Mueller S, Gupta N, Tihan T, Bollen AW, Northcott PA, Kool M, Pfister S, Korshunov A, Perry A, Solomon DA. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathol. 2018 Apr; 135(4):635-638.
    View on PubMed
  10. Pekmezci M, Stevers M, Phillips JJ, Van Ziffle J, Bastian BC, Tsankova NM, Kleinschmidt-DeMasters BK, Rosenblum MK, Tihan T, Perry A, Solomon DA. Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. Acta Neuropathol. 2018 Mar; 135(3):485-488.
    View on PubMed
  11. Goode B, Joseph NM, Stevers M, Van Ziffle J, Onodera C, Talevich E, Grenert JP, Yeh I, Bastian BC, Phillips JJ, Garg K, Rabban JT, Zaloudek C, Solomon DA. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Mod Pathol. 2018 Apr; 31(4):660-673.
    View on PubMed
  12. Shain AH, Bastian BC. Filling the gaps in the genomic catalogue of melanoma subtypes. Pigment Cell Melanoma Res. 2017 Jan; 30(6):508-509.
    View on PubMed
  13. Yeh I, Lang UE, Durieux E, Tee MK, Jorapur A, Shain AH, Haddad V, Pissaloux D, Chen X, Cerroni L, Judson RL, LeBoit PE, McCalmont TH, Bastian BC, de la Fouchardière A. Combined activation of MAP kinase pathway and ß-catenin signaling cause deep penetrating nevi. Nat Commun. 2017 09 21; 8(1):644.
    View on PubMed
  14. Chiba K, Lorbeer FK, Shain AH, McSwiggen DT, Schruf E, Oh A, Ryu J, Darzacq X, Bastian BC, Hockemeyer D. Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism. Science. 2017 09 29; 357(6358):1416-1420.
    View on PubMed
  15. Foley N, Van Ziffle J, Yu J, Qi Z, Grenert JP, Yeh I, Bastian B, Kogan S, Mannis GN. Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation? Cancer Genet. 2017 Oct; 216-217:74-78.
    View on PubMed
  16. Chen X, Wu Q, Depeille P, Chen P, Thornton S, Kalirai H, Coupland SE, Roose JP, Bastian BC. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. Cancer Cell. 2017 05 08; 31(5):685-696.e6.
    View on PubMed
  17. Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein S, Torkildson J, Samuel D, Bloomer M, Campomanes AGA, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn WM, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaides T, Solomon DA. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol. 2017 05 01; 19(5):699-709.
    View on PubMed
  18. Eluri M, Feneran A, Bordeaux JS, Ruben B, Ostrowski S, Bastian BC, Honda K. Multiple Merkel cell carcinomas: Late metastasis or multiple primary tumors? A molecular study. JAAD Case Rep. 2017 Mar; 3(2):131-134.
    View on PubMed
  19. Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep. 2017 Mar 13; 7:44206.
    View on PubMed
  20. Joseph NM, Chen YY, Nasr A, Yeh I, Talevich E, Onodera C, Bastian BC, Rabban JT, Garg K, Zaloudek C, Solomon DA. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Mod Pathol. 2017 Feb; 30(2):246-254.
    View on PubMed

Go to UCSF Profiles, powered by CTSI